Doubts about the effectiveness of the Oxford vaccine

Doubts about the effectiveness of the Oxford vaccine 7
Doubts about the effectiveness of the Oxford vaccine 7

This information was released a few days after pharmaceutical company AstraZeneca and Oxford University announced that the vaccine in phase three trials was 70% effective on average, and 90% effective for low doses.

On November 25, the Oxford University team said that due to some vaccine vials not having enough concentration, nearly 25% of volunteers only received half of the first dose, and a month later received a full dose.

Before that, the researchers carefully explained each experimental step and how to analyze the results.

The trial is part of large studies taking place in the UK and Brazil, to determine the optimal vaccine dose and evaluate safety and effectiveness.

However, the test results raise many questions.

According to experts, because the number of volunteers vaccinated with 1.5 shots is relatively small, 2,741 people, it is difficult to determine whether the effectiveness of the vaccine with this group is real or a statistical error.

Volunteers who received the low-dose vaccine were all under 56 years old.

Scientists at the Jenner Institute, Oxford University research vaccines.

In addition, the decision to combine results from two volunteer groups is also controversial, said David Salisbury and colleagues of the global health program, Chatham House.

`You ran two studies using different vaccine doses and came up with a common result that is not representative of any one dose,` Salisbury said.

Previously, Andrew Pollard, principal investigator of the Oxford trial, said it was unclear why the Covid-19 vaccine doses had different results.

Sarah Gilbert, one of the study leaders, predicts they may have provided exactly the right amount of vaccine to trigger the best immune response.

Oxford University and its partners will publish detailed trial results in medical journals before submitting applications for use licenses to British regulatory agencies.

On November 24, Moncef Slaoui, head of the US Operation Speed Force program, said US officials are trying to determine the level of immune response of the Oxford/AstraZeneca vaccine, and may adjust testing in the US.

`We want results that are based on data and science,` he emphasized.

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *